SCM
BCAX

SCS Capital Management’s Bicara Therapeutics BCAX Stock Holding History

SCS Capital Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.59M Hold
53,430
– – 0.02% 236
2026
Q1 		$1.06M Hold
53,430
– – 0.01% 269
2025
Q4 		$899K Hold
53,430
– – 0.01% 293
2025
Q3 		$844K Hold
53,430
– – 0.01% 305
2025
Q2 		$496K Buy
+53,430
New +$637K 0.01% 389

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCS Capital Management's BCAX Position: Q2 2026 in Review

SCS Capital Management held its Bicara Therapeutics (BCAX) position steady in Q2 2026 at 53,430 shares worth $1.59M. The position accounts for 0.02% of the portfolio, ranked #236.

SCS Capital Management first reported a position in BCAX in Q2 2025 and has held it in 5 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • SCS Capital Management held 53,430 shares of Bicara Therapeutics worth $1.59M as of Q2 2026.
  • SCS Capital Management left its Bicara Therapeutics share count unchanged in Q2 2026.
  • Bicara Therapeutics made up 0.02% of SCS Capital Management's portfolio in Q2 2026, its #236 holding.
  • SCS Capital Management first reported a position in Bicara Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on SCS Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.